# Data Sheet (Cat.No.T12481)



#### Pipecuronium bromide

### **Chemical Properties**


CAS No.: 52212-02-9

Formula: C35H62Br2N4O4

Molecular Weight: 762.7

Appearance: N/A

Storage:  $0-4^{\circ}\text{C}$  for short term (days to weeks), or  $-20^{\circ}\text{C}$  for long term (months).



## **Biological Description**

Description	Pipecuronium bromide is a powerful competitive antagonist of nAChR(Kd of 3.06 μM).	
Targets(IC <sub>50</sub> )	nAChR: None	

## Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

#### **Preparing Stock Solutions**

	1mg	5mg	10mg
1 mM	1.311 mL	6.556 mL	13.111 mL
5 mM	0.262 mL	1.311 mL	2.622 mL
10 mM	0.131 mL	0.656 mL	1.311 mL
50 mM	0.026 mL	0.131 mL	0.262 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

#### Reference

- 1. Tassonyi E, et al. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial. Anesth Analg. 2015 Aug;121(2):373-80.
- 2. Tassonyi E, et al. Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial. Anesth Analg. 2018 Dec;127(6):1344-1350.
- 3. Alánt O, et al. First clinical experience with a new neuromuscular blocker pipecurium bromide. Arzneimittelforschung. 1980;30(2a):374-9.
- 5. Kárpáti E, et al. Investigation of neuromuscular blocking agents at Richter Ltd. Acta Pharm Hung. 2002;72(1):37-48.

Page 1 of 2 www.targetmol.com

### Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only  $\cdot$  Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com